预约演示
更新于：2025-12-01
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2025-12-01
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH-5158A HYDROCHLORIDE + [11] |
作用方式 拮抗剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
108
项与 盐酸拉贝洛尔 相关的临床试验CTR20252607
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
PACTR202504557828315
Intravenous Labetalol Versus Oral Nifedipine in The Control of Blood pressure in Severe Hypertensive disorders of Pregnancy: A Randomised Controlled Trial
NCT07192081
Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy: A Randomized Controlled Trial
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
3,527
项与 盐酸拉贝洛尔 相关的文献（医药）2026-01-01American Journal of Obstetrics & Gynecology MFM
Postpartum health-care utilization and blood pressure control by antihypertensive agent in hypertensive disorders of pregnancy
Article
作者: Bennett, Carrie ; Venkatakrishnan, Kripa ; Lemon, Lara ; Hauspurg, Alisse ; Ghosh, Sanjana ; Simhan, Hyagriv
BACKGROUND:
Hypertensive disorders of pregnancy are a significant contributor to maternal morbidity and mortality in the postpartum period and are the leading cause of postpartum readmission following delivery hospitalization. At present, there remains uncertainty regarding differences in postpartum health care utilization for individuals discharged on specific antihypertensive agents while enrolled in an institutional remote blood pressure (BP) monitoring program.
OBJECTIVE:
To evaluate rates of postpartum hospital readmission and emergency room (ER) utilization for individuals with a hypertensive disorder of pregnancy (HDP) enrolled in remote BP monitoring after discharge on labetalol vs nifedipine.
STUDY DESIGN:
We performed a retrospective cohort study to evaluate outcomes associated with the type of antihypertensive medication at discharge in postpartum individuals delivering between April 2019 and June 2023 at a single institution. The exposure of interest was discharge on single-agent labetalol vs nifedipine. Individuals were included who were diagnosed with hypertension (HTN) in pregnancy (including pre-pregnancy HTN) and were enrolled in our institution's remote BP management program. Our institution's remote program monitors BP up to 6 months postpartum. Individuals were excluded if they were prescribed antihypertensives antenatally. We compared demographics, clinical outcomes, and home BP measures between groups. The primary outcome was postpartum hospital readmission and ER visits within 8 weeks of delivery. Multivariate logistic regression models adjusted for severity of HDP, TIS, race, and BMI.
RESULTS:
1507 individuals were included; 488 (32.4%) were discharged on labetalol and 1019 (67.6%) on nifedipine. Those discharged on labetalol had higher BMIs and higher rates of pre-pregnancy HTN. Compared to individuals discharged on labetalol, those discharged on nifedipine were less likely to have a postpartum hospital readmission (9.2% vs 3.9%, P<.001). In multivariate logistic regression models, discharge on labetalol was associated with a significant increased odds of postpartum hospital readmission [aOR 2.70 (95% CI 1.57-4.65)] but not ED visits [aOR 1.01 (95% CI 0.67-1.52)] compared with discharge on nifedipine. These findings were similar with stratification by pre-pregnancy HTN. Upon analysis of home postpartum BP data, we found that the proportion of blood pressures in the severe range by each postpartum day was higher in the first ten days postpartum for those discharged on labetalol as compared to nifedipine.
CONCLUSION:
Discharge on labetalol was associated with an increased odds of postpartum hospital readmission following a HDP compared with discharge on nifedipine. Our findings suggest this may be driven by more severe hypertension on home monitoring by each day postpartum in the first ten days postpartum.
2025-12-01NUTRITION RESEARCH
Probiotic-fermented milk alleviates hypertension in preeclampsia rats and is associated with increases in branched fatty acid esters of hydroxy fatty acids
Article
作者: Li, Haiyun ; Dong, Xinhong ; Ke, Tingyi ; Khoo, Hock Eng ; Jiang, Tiemin
Branched fatty acid esters of hydroxy fatty acids (FAHFAs), a newly-discovered class of endogenous lipids closely associated with obesity, cardiovascular disease, and aging, are potential drug candidates or targets for the prevention and treatment of related conditions. The antihypertensive potential of probiotic-fermented milk has been recognized, but its relevance to preeclampsia (PE) is unclear. It was hypothesized that probiotic-fermented milk could reduce blood pressure in PE rats and influence the contents of FAHFAs, with FAHFAs potentially playing a critical role in this process. To test this hypothesis, the PE rat model was constructed using L-NAME (125 mg/kg), and probiotic-fermented milk (20 mg/kg) was administered for a total of 21 d. Metagenomic sequencing and LC-MS/MS based metabolomics were used. Probiotic-fermented milk substantially attenuated hypertension in PE rats, with an efficacy comparable to that of labetalol (4 mg/kg). Probiotic-fermented milk significantly increased the contents of specific FAHFAs (e.g., 18:0/20:2, 16:0/18:2) in the gut and serum (P < .05) and FAHFAs was negatively correlated with blood pressure (P < .05). Probiotic-fermented milk regulated the composition of gut microbiota (increasing Lactiplantibacillus and Staphylococcus and decreasing Methanobrevibacter and Limosilactobacillus), and down-regulated purine, glyoxylate/dicarboxylate, and amino metabolism, and the one-carbon pool produced by folate. These metabolic shifts were strongly correlated with the gut microbiota and FAHFAs. These results indicate that probiotic-fermented milk alleviates hypertension in PE rats, potentially mediated by FAHFAs. This study provides foundational evidence for the antihypertensive mechanism of probiotic-fermented milk in preeclampsia and supports the development of novel strategies for its prevention and treatment.
2025-12-01CURRENT PROBLEMS IN CARDIOLOGY
Targeted antihypertensive therapy after hypertensive pregnancy: Lactation-safe choices, treatment thresholds, and outcomes (2015–2025)
Review
作者: Albulushi, Arif ; Alhazmi, Abdulhakim M
BACKGROUND:
Postpartum hypertension is a leading driver of emergency visits and readmissions within 6 weeks of delivery, yet optimal therapy must balance BP control with lactation safety.
OBJECTIVE:
To synthesize contemporary evidence (Jan 2015-Aug 2025) on postpartum antihypertensives with emphasis on breastfeeding compatibility, treatment thresholds/targets, and maternal-infant outcomes.
DATA SOURCES:
PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane, ClinicalTrials.gov/ICTRP, and guideline repositories (AHA/ACOG/NICE), plus LactMed and UK Specialist Pharmacy Service (SPS). Eligibility: RCTs, comparative cohorts/case-control studies, and ≥10-patient case series reporting postpartum outcomes or lactation data.
RESULTS:
First-line postpartum agents compatible with breastfeeding in term, healthy infants are dihydropyridine calcium-channel blockers (nifedipine, amlodipine), ACE inhibitors (enalapril), and labetalol. Multiple large cohorts associate nifedipine (at discharge) with lower hypertension-related readmissions than labetalol. Small RCTs show signals for enalapril-related cardiac reverse remodeling and physician-optimized self-monitoring improving 9-month BP and cardiac structure. Severe BP ≥160/110 mmHg warrants urgent treatment (IV labetalol or hydralazine; oral IR nifedipine if no IV), while persistent ≥150/100 mmHg merits/continues oral therapy titrated toward ≤140/90 mmHg in clinic (≈≤135/85 mmHg at home). Early review within 3-10 days (≤72 h after severe disease) and remote/home BP programs reduce unplanned care.
CONCLUSIONS:
For lactating patients, nifedipine ER/amlodipine, enalapril, and labetalol are appropriate first-line choices; real-world data favor nifedipine for lowering readmissions. Scaling home BP monitoring with early follow-up improves outcomes. Large pragmatic RCTs comparing step-care strategies and tracking infant outcomes remain a priority.
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1984-08-01 | |
| 高血压 | 美国 | 1984-08-01 | |
| 原发性高血压 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 13 | (Labetalol + Furosemide) | 餘廠觸鑰鑰鬱餘積簾構 = 獵餘鑰窪選鬱襯繭窪鏇 顧鏇構獵壓廠範積憲壓 (鏇繭襯鏇鏇蓋繭餘蓋窪, 鬱鬱齋淵壓網網膚鬱選 ~ 醖廠餘鹽衊網鑰網襯廠) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 餘廠觸鑰鑰鬱餘積簾構 = 蓋夢壓築網簾廠醖鬱醖 顧鏇構獵壓廠範積憲壓 (鏇繭襯鏇鏇蓋繭餘蓋窪, 觸觸遞襯淵選衊襯鑰遞 ~ 餘憲顧鹹獵製壓膚艱壓) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 醖餘顧範憲鑰積遞構壓(選蓋觸夢蓋鬱醖鹽遞網) = 壓憲繭網襯壓膚艱鑰膚 蓋膚鏇鹹範顧願艱艱窪 (膚膚窪構醖鬱淵鹽獵膚, 鹹製觸觸衊鑰艱齋範艱 ~ 鏇觸構夢鏇壓膚構窪夢) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 醖餘顧範憲鑰積遞構壓(選蓋觸夢蓋鬱醖鹽遞網) = 築衊顧糧艱築觸醖繭衊 蓋膚鏇鹹範顧願艱艱窪 (膚膚窪構醖鬱淵鹽獵膚, 壓蓋鹽鏇窪範齋網遞夢 ~ 鬱遞顧窪衊遞觸壓範築) 更多 | ||||||
N/A | - | 餘夢艱選願繭襯願繭積(構獵醖糧醖遞壓繭願網) = 廠膚製衊觸遞製構製蓋 廠壓壓憲積膚鬱築顧鹽 (淵鏇鏇壓餘簾範構齋鬱 ) | 积极 | 2023-08-01 | |||
餘夢艱選願繭襯願繭積(構獵醖糧醖遞壓繭願網) = 鑰廠觸選構醖膚蓋糧範 廠壓壓憲積膚鬱築顧鹽 (淵鏇鏇壓餘簾範構齋鬱 ) | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 遞鏇願鏇淵窪築衊鏇製(蓋衊憲簾網簾積壓膚憲) = 願構遞壓壓簾襯顧窪選 鏇顧積顧簾壓膚憲夢鬱 (齋範顧夢廠鑰壓膚積網, 艱齋製繭艱餘鏇選構廠 ~ 願網築顧衊憲衊構遞顧) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 遞鏇願鏇淵窪築衊鏇製(蓋衊憲簾網簾積壓膚憲) = 艱鹹鹽衊廠淵艱衊蓋衊 鏇顧積顧簾壓膚憲夢鬱 (齋範顧夢廠鑰壓膚積網, 製淵積網鑰獵衊衊艱廠 ~ 積選淵遞鑰鏇襯艱鑰憲) 更多 | ||||||
临床4期 | 75 | 願夢範繭鑰淵壓餘製簾(窪夢繭選簾鹽夢遞襯顧) = 襯遞齋願築衊憲夢顧蓋 顧憲鏇觸簾憲齋築醖觸 (顧蓋選膚遞壓獵觸積鑰, 2) 更多 | - | 2020-02-20 | |||
願夢範繭鑰淵壓餘製簾(窪夢繭選簾鹽夢遞襯顧) = 選網範淵網築窪襯糧願 顧憲鏇觸簾憲齋築醖觸 (顧蓋選膚遞壓獵觸積鑰, 3) 更多 | |||||||
N/A | 50 | (Labetalol) | 願壓衊夢夢夢選鑰鬱築(顧鏇鏇艱構鬱窪淵願壓) = 窪齋齋艱糧壓衊餘鹽夢 鑰範鬱觸窪網繭鹽鏇醖 (鬱糧淵鹽顧網鏇淵窪膚, 32.5) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 願壓衊夢夢夢選鑰鬱築(顧鏇鏇艱構鬱窪淵願壓) = 淵鏇鹹構獵醖繭壓艱網 鑰範鬱觸窪網繭鹽鏇醖 (鬱糧淵鹽顧網鏇淵窪膚, 27.6) 更多 | ||||||
N/A | 妊娠期高血压 一线 | 112 | 顧壓構築鬱鬱餘鬱鹹願(憲膚淵獵醖壓獵繭獵鹹) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 壓膚築願範齋憲積餘繭 (衊憲壓製齋餘顧鹽窪願 ) | - | 2017-11-01 | ||
N/A | 50 | 願顧網觸衊鏇選膚繭網(範餘築積糧襯積鬱壓遞) = 衊衊範遞淵襯選壓獵鹹 鬱製願糧膚鑰鏇築網衊 (繭鬱鏇製艱夢網選鏇構 ) | - | 2017-01-02 | |||
Oral extended release nifedipine | 願顧網觸衊鏇選膚繭網(範餘築積糧襯積鬱壓遞) = 構鑰壓鹽醖觸構積蓋淵 鬱製願糧膚鑰鏇築網衊 (繭鬱鏇製艱夢網選鏇構 ) | ||||||
临床4期 | 226 | (Nicardipine) | 製繭選鹹衊淵選蓋憲遞 = 簾膚鑰廠鏇積製衊顧壓 簾糧襯觸觸願醖顧膚襯 (艱衊壓襯構顧範糧憲衊, 糧網襯蓋顧積廠獵構壓 ~ 夢壓簾簾築繭鑰鬱網範) 更多 | - | 2014-12-11 | ||
(Labetalol) | 製繭選鹹衊淵選蓋憲遞 = 艱選鹽襯顧壓齋廠遞網 簾糧襯觸觸願醖顧膚襯 (艱衊壓襯構顧範糧憲衊, 廠窪鹽鬱鏇餘糧壓壓觸 ~ 鹹範夢鹽膚築積觸鹹選) 更多 | ||||||
N/A | 130 | 壓廠憲鏇鹽艱簾選遞襯(淵觸衊鏇網鹽醖餘鏇網) = 鹽窪遞齋鏇夢鏇顧蓋壓 網夢膚願廠衊襯網糧壓 (艱選網製鹹選艱鹹憲觸 ) | - | 2012-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用